Compare Johnson & Johnson (JNJ) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Plby Group Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Plby Group Inc trades at $0.98 (market cap $118.21M). The key difference: Johnson & Johnson is far larger — about 5228.7× Plby Group Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Plby Group Inc for 24 Days on average.
| JNJ | PLBY | |
|---|---|---|
Market Cap | $618.09B | $118.21M |
Volume | 6,050,983 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $2.71 |
52-Week Low | $186.00 | $0.98 |
Typical Hold Time | 129 Days | 24 Days |
Enterprise Value | $646.37B | $263.80M |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
PLBY trades at $0.9867, down 3.26% today, amid bearish technical signals but with improving fundamentals. Recent earnings show a Q2 2026 beat, and cash flow turned positive in 2025. The company is expanding leadership to drive growth, yet faces high debt and negative equity. Analyst consensus is 75% buy, reflecting optimism on turnaround efforts.
Outlook hinges on execution of growth initiatives and debt management. Opportunities include brand licensing expansion and media strategy, but risks from high leverage and competitive pressures persist. Investors should weigh improving operational trends against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
